Investigating how MIF-CD74 signaling affects immune responses in pancreatic cancer.
Role of MIF-CD74 signaling as an immune regulator and therapy target in pancreas cancer.
This study is looking at how certain immune cells in pancreatic cancer might be holding back the body's ability to fight the disease, and it hopes to find new ways to boost the immune response to help patients with this tough cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA North Texas Health Care System NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11052061 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a highly lethal cancer with few treatment options. It aims to understand how the immune system is suppressed within the tumor microenvironment, particularly by tumor-associated macrophages (TAMs), which can either promote or inhibit anti-tumor responses. The study will explore the role of the MIF-CD74 signaling pathway in regulating TAM activation and its potential as a target for immunotherapy, with the goal of enhancing T-cell responses against cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may benefit from enhanced immune responses to their cancer.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy strategies that improve treatment outcomes for patients with pancreatic cancer.
How similar studies have performed: While the specific approach of targeting MIF-CD74 signaling in PDA is novel, similar strategies targeting immune modulation in cancer have shown promise in other studies.
Where this research is happening
Dallas, United States
- VA North Texas Health Care System — Dallas, United States (Active)
Researchers
- Principal investigator: Maddipati, Ravikanth — VA North Texas Health Care System
- Study coordinator: Maddipati, Ravikanth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.